文献速递介入腹部CTMRUS

使用可分离集束电极的双开关单极射频消融:初步研究

Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study.
PubMed 文献 · Korean J Radiol · 2017-07-17

这项前瞻性研究评估了双开关单极射频消融治疗肝细胞癌的安全性和疗效,并与历史对照组单开关单极射频消融进行回顾性比较。双开关单极射频消融实现了100%技术成功率和98.1%技术有效率,2年局部肿瘤进展率为4.3%,主要并发症发生率为3.8%,其消融体积和能量输送效率显著高于单开关单极射频消融,主要并发症和技术有效率无显著差异。

要点

  • 双开关单极射频消融治疗小肝癌的技术成功率为100%,技术有效率为98.1%。
  • 双开关单极射频消融的2年局部肿瘤进展率为4.3%,与单开关单极射频消融的10.1%无显著差异(p=0.15)。
  • 双开关单极射频消融单位时间消融体积和能量输送均显著高于单开关单极射频消融(p<0.01)。

核心结论

  • 使用可分离集束电极的双开关单极射频消融是安全的,对小肝癌提供了高的局部肿瘤控制和良好的初步临床结果,至少与单开关单极射频消融相当。

研究设计与样本

  • 前瞻性评估双开关单极射频消融治疗肝细胞癌的安全性和疗效,并回顾性比较历史对照组单开关单极射频消融;双开关单极射频消融组纳入52例肝细胞癌患者,使用可分离集束电极和双发生器;历史对照组为249例回顾性纳入的接受单开关单极射频消融的肝细胞癌患者;通过术后和随访影像评估技术参数、并发症、技术成功、技术有效性和局部肿瘤进展率。

诊断标准与关键数值

  • 双开关单极射频消融组:技术成功率100%,技术有效率98.1%,2年局部肿瘤进展率4.3%,主要并发症发生率3.8%(2/52,包括胸腔积液和心包积液);单开关单极射频消融组:技术有效率96.4%,2年局部肿瘤进展率10.1%,主要并发症发生率4.4%;两组技术有效率和主要并发症无显著差异(p=1.00),2年局部肿瘤进展率无显著差异(p=0.15)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To prospectively evaluate the safety and therapeutic effectiveness of dual-switching monopolar (DSM) radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), and to retrospectively compare the results with those of single-switching monopolar (SSM) RFA in a historical control group.

MATERIALS AND METHODS: This study was approved by the Institutional Review Board, with informed consent obtained from all patients. Fifty-two HCC patients who underwent DSM-RFA using a separable clustered electrode and dual-generators were prospectively enrolled. Technical parameters, complications, technical success, technical effectiveness, and local tumor progression (LTP) rates were evaluated by means of post-procedural and follow-up imaging. Thereafter, the outcome of DSM-RFA was compared with those of 249 retrospectively included HCC patients treated with SSM-RFA.

RESULTS: There were two major complications (3.8%, 2/52) including pleural and pericardial effusion in the DSM-RFA group. The DSM-RFA yielded a 100% technical success rate, a 98.1% technical effectiveness rate, and a 4.3% 2-year LTP rate. In a retrospective comparison between the two groups, DSM-RFA created significantly larger ablation volume (4.20 ± 2.07 cm3/min vs. 3.03 ± 1.99 cm3/min, p < 0.01), and delivered higher energy (1.43 ± 0.37 kcal/min vs. 1.25 ± 0.50 kcal/min, p < 0.01) per given time, than SSM-RFA. There was no significant difference in major procedure-related complications (3.8% vs. 4.4%) and technical effectiveness rate (98.1% vs. 96.4%) between the two groups (p = 1.00). In addition, the 2-year LTP rate of DSM-RFA and SSM-RFA were 4.3% and 10.1%, respectively (p = 0.15).

CONCLUSION: DSM-RFA using a separable clustered electrode is safe and provides high local tumor control and good preliminary clinical outcome for small HCCs, which are at least comparable to those of SSM-RFA.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Choi TW, Lee JM, Lee DH, et al. Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean J Radiol. 2017. PMID: 28860897. doi:10.3348/kjr.2017.18.5.799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。